News Releases

Servier’s VORANIGO® (vorasidenib) and TIBSOVO® (ivosidenib) Nominated for 2026 Prix Galien International Awards

Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business

Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio

Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.

Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026